<DOC>
	<DOCNO>NCT01384422</DOCNO>
	<brief_summary>- Thirty six patient suffer active rheumatoid arthritis despite continued treatment methotrexate evaluate improvement disease activity take GLPG0634 match placebo 4 week . - During course study , patient also examine side effect may occur , amount GLPG0634 present blood well effect GLPG0634 disease- mechanism action-related parameter blood determine .</brief_summary>
	<brief_title>Safety Preliminary Efficacy GLPG0634 Methotrexate-refractory Active Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Have active RA show five swollen joint ( 66joint count ) , five tender joint ( 68joint count ) , serum CRP ≥1.0 mg/dL ; Have receive methotrexate six month longer stable dose 7.5 25 mg/week ( extremes include ) least four week prior screen willing continue regimen duration study ; If take oral steroid , dose ≤10 mg/day prednisone prednisone equivalent stable least four week prior screen ; If take nonsteroidal antiinflammatory drug ( NSAIDs ) , must stable dose least two week prior screen ; Female subject must negative pregnancy test unless surgically sterile postmenopausal least one year ( 12 consecutive month without menses ) ; Women childbearing potential must use medically acceptable mean birth control agree continue use study least four week last dose study drug . Sexually active men must agree use medically acceptable form contraception study continue use least 3 month last dose study drug ; Able willing sign inform consent prior screen evaluation agree schedule assessment . Treatment diseasemodifying antirheumatic drug ( DMARDs ) , background methotrexate ; Current previous RA treatment biological agent , exception biologics administer clinical study set six month prior screen ( 12 month rituximab B cell deplete agent ) ; Previous treatment time cytotoxic agent , methotrexate , screen ; Receipt intraarticular parenteral corticosteroid injection within four week prior screen ; Known hypersensitivity study drug ingredient significant allergic reaction drug determine Investigator , anaphylaxis , require hospitalization ; Positive serology human immunodeficiency virus ( HIV ) 1 2 hepatitis B C , history hepatitis cause exception hepatitis A ; History inflammatory rheumatological disorder RA ; History tuberculosis ( TB ) infection ; Pregnant lactate woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>methotrexate-refractory</keyword>
</DOC>